News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Conference News AHA 2021 Dietary Patterns, Social Pressures: AHA Offers New Nutrition Advice Caitlin E. Cox November 19, 2021
News Conference News AHA 2021 Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF Michael O'Riordan November 19, 2021
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward Todd Neale November 16, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Conference News AHA 2021 An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops Shelley Wood November 15, 2021
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Daily News Countries With Sodium Targets Have the Least-Salty Processed Meats L.A. McKeown October 19, 2021
News Daily News FDA Issues New Guidance on Sodium Targets for Food Industry L.A. McKeown October 14, 2021
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Daily News AHA Stresses Benefit of Meds, Surgery for Obesity-Related Hypertension Yael L. Maxwell September 23, 2021
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News ESC 2021 PET Imaging Detects Degeneration After TAVI as Well as Surgical, Native Valves Yael L. Maxwell September 02, 2021
News Conference News ESC 2021 Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD Michael O'Riordan August 29, 2021
News Conference News ESC 2021 New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT Shelley Wood August 28, 2021
News Conference News ESC 2021 Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD Michael O'Riordan August 28, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021